Wednesday, July 8, 2026

pharma · Non-Hodgkin Lymphoma · Advanced Solid Tumors · ADCT

ADC Therapeutics

ADC Therapeutics clinical programs — 14 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Lausanne, Vaud, Switzerland, CH HQ
2011 Founded
272 Employees
Public company Type
ADCT · NYSE Ticker
Company details
Status
Public
HQ
Lausanne, Vaud, Switzerland, CH
Founded
2011
Employees
272
Programs
30
Drugs
15
Patents
22
Intelligence · Clinical Programs

ADC Therapeutics projects

14 ClinicalTrials.gov programs sponsored by ADC Therapeutics.

ADC Therapeutics has 14 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. ADCT-301

    ADC Therapeutics SA

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule terminated

    1 trial
  2. ADCT-602

    ADC Therapeutics SA

    Blasts 5 Percent or More of Bone Marrow Nucleated Cells

    phase 2 mab terminated

    1 trial
  3. Camidanlumab Tesirine

    ADC Therapeutics SA

    Relapsed Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial
  4. Cyclophosphamide

    ADC Therapeutics SA

    Double-Expressor Lymphoma

    phase 2 small molecule active

    1 trial
  5. Epcoritamab

    ADC Therapeutics SA

    Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial
  6. Loncastuximab Tesirine

    ADC Therapeutics SA

    Waldenstrom Macroglobulinemia

    phase 2 small molecule active

    1 trial
  7. Loncastuximab Tesirine

    ADC Therapeutics SA

    Diffuse Large B-cell Lymphoma

    phase 2 small molecule active

    4 trials
  8. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial
  9. Loncastuximab Tesirine

    ADC Therapeutics SA

    Relapsed or Refractory Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial
  10. Loncastuximab tesirine

    ADC Therapeutics SA

    Follicular Lymphoma

    phase 2 small molecule active

    1 trial
  11. Loncastuximab tesirine

    ADC Therapeutics SA

    Post-transplant Lymphoproliferative Disorder

    phase 2 small molecule active

    1 trial
  12. Loncastuximab tesirine

    ADC Therapeutics SA

    Diffuse Large B-Cell Lymphoma Refractory

    phase 2 small molecule completed

    1 trial
  13. Loncastuximab tesirine 150 µg/Kg

    ADC Therapeutics SA

    Marginal Zone Lymphoma

    phase 2 small molecule active

    1 trial
  14. imvotamab

    ADC Therapeutics SA

    Non-Hodgkin Lymphoma

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does ADC Therapeutics have?

14 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.